The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Not sure RENX has any capability to engage with regulatory powers outside the US which has been their focus…..and they cant afford to which is where a licensing deal / takeover makes sense if this product is viable, it will have application in most populations, particularly the fatter western populations and the mass populations in China and India where there is still a lot of obesity caused by poor diet rather than over consumption.
We know roughly what the pipeline news will be this year and the in-market China sales. Unknowns are how successful Takeda will be ex-China and whether Sovlep will attract a partner paying a decent upfront fee.
Beyond that there are potential corporate actions to sell / demerge the subsidiary businesses which is possible and whether CKHH wants a strategic M&A action which has appeared unlikely in the past. CKHHs need to monetize its investment in HCM is likely low, it reports on Thursday next week.
What does seem clear is that HCM does not appear to need to raise any further equity finance. Indeed it looks increasingly likely that it already has surplus capital but it is unlikely to return any of that to SH before 2027.
With the above in mind, I would think HCM should become less volatile and more news driven but what do I know.
At the risk of being contradicted by the market, the initial profit taking that caused a retreat below 100p seems to have been overcome and there seems to be more support to sustain the SP above 100.
As mentioned in earlier posts, I expect to see 20p added over the year, and I suspect this will be in steps with the HY and FY numbers. Of course a market movement could override this expectation but the annuity market seems to be set fair at the moment.
They paid out 100% of what they earned in dividend and buy back…..last two years they have bought 3.6bn x2 and it has done them no favours….
Pru needs to up its dividend rather than BB as it pays a low dividend - if it were a UK Life Office we would expect 70p for an £8 share price….they say there is growth, then invest in the business and pay better dividends to shareholders to see the share price rise.
The astrologers/chartists have got this one badly wrong…..apparently there was a ‘death cross’ at the end of Feb with the ADRs around $15…..that is said to be a very bad sign….
Maybe there will be some news that hopes to explain this weeks exuberance…or more likely there wont.
Davey will be kicking himself if he really did sell up.
There may well be some contagion with other businesses but STJ thought itself the biggest and the best and it incentivised /rewarded the greediest.
The salesmen and supporting staff where I worked always wanted to copy the STJ schemes and compliance/HR had to stop them implementing the worst aspects.
There will be self-justified reasons to continue charging for ongoing advice when it was not received - the client did not respond, the client was told the fee etc.
Let’s be honest about ongoing advice - for most people unless there is a life event a three or even 5 year review is ok. And for most investments performance will vary around the average. Managed portfolios where the investment advisory firm can change investment funds within the overall aim of the client and contact with the client to check there is no major change is good enough for most clients and should carry minimal cost.
And Nasdaq has moved to a £3 equivalent……
All those inexplicable angst inducing falls after the FDA approval near wiped out in a few days of without any new information.
Innovent has moved sharply up too, but Beigene/Junshi much less.
It was a late late show in HK with it only really moving up towards the end of the day.
The UK and US pre-market seem to be taking it a little further today.
FOMO seems to have taken hold.
These rapid changes in value help no-one and only convince me that this is a long term buy and hold proposition….the future seems more certain.
CKHH reports on 21 March….I am not expected them to make any announcements re Hutchmed, but some more acknowledgement within their results pack would be a start.
Abandon ship!
The dead cat bounced but was not brought back to life.
This is now sinking gradually lower and I suspect Porsche is rightly predicting the SP starting with a 3.
This is only getting worse for the next 18m, with a recovery only starting in 2027.
I suppose it relates to statements at the Party get together…overall I dont like these no news movements, they can easily be reversed.
For me, the next important piece of news will be the Q1 24 sales made by Takeda in the US.
Nov/Dec was $15m, I am hoping for building momentum with $30m in Jan-Mar and that they can build this up to $50m per quarter by the end of the year, giving in-market sales of around $150m which would generate a royalty to HCM of $20m plus other manufacturing and support charges. It was interesting that the EU market is considerable larger than the US (although the pricing may be lower when that is determined), hence approval by EMA is also to be eagerly awaited, hopefully there will be meaningful EU sales later this year.
Some stronger results coming through…today’s update is helpful, but the range is wide…room for some assumption changes/provisions but the positive improvement is there for all to see.
Sadly RSA seems to be limping towards becoming a basket case.
AIA reports on Thursday (after HK close)….Q3 showed positive progress with value of new business ahead 35% on 2022 and China up 20% in Q3.
It will be interesting to see what AIA reports…but those figures dont merit the hammering Pru and AIA share prices have taken…
Who would have thought:
1 people take their pets to a local vet
2 the vets will copy the practices of private healthcare and private dentistry
3 healthcare no longer tolerates one man bands/small practices which is where the cranks reside
4 consolidation leads to concentrations (4 but perhaps 3 mobile networks are enough? So why concerned about 6 vet groups).
5 there are now secondary referral units akin to private hospitals…these provide much more specialist pet healthcare and are £££ to build, staff and maintain.
The CMA seems to be talking up its enforcement / remediation role…but I am not sure what they are going to be able to do beyond making vets tell customers they can buy services elsewhere and they may be cheaper (but that will involve more effort by the customer and delays in administering medication so I Don’t expect a great change in customer behaviour).
Today would appear to be a buying opportunity for those that expect modest CMA recommendations.